Salix Acquires Santarus: Synergies And Analyst Sentiment
This article was originally published in The Pink Sheet Daily
Executive Summary
Some analysts balked, but Salix management defended the price the company is paying for Santarus on a Nov. 7 earnings call, arguing that synergies from an integration support the valuation of six to seven times the sales price.
You may also be interested in...
ViroPharma Talks Cinryze Sales, EU Launches
ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.
Persistence, Secondary Endpoints Helped Shire Get FDA Nod For Firazyr Novel PRO
FDA questioned the validity of icatibant’s patient-reported outcomes instrument during a first-cycle review and found it “difficult to interpret.” But conducting a third trial and running validity testing after FDA issued final PRO guidance, as well as key secondary endpoints that supported the treatment effect, helped sway regulators.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.